NEW YORK, March 23, 2015 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of Arizona on behalf of all persons or entities that purchased the securities of Accelerate Diagnostics, Inc. ("Accelerate Diagnostics" or the "Company") (Nasdaq:AXDX) between March 7, 2014 and February 17, 2015, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").
The Complaint alleges that during the Class Period, AXDX made false and/or deceptive statements, and failed to divulge material adverse facts about the Company's business, operations, prospects and performance. Explicitly, the complaint alleges that Defendants made deceptive statements and/or failed to disclose that the Company's BACcel or ID/AST system requires a positive blood culture, contrary to the information provided in their previous public filings.
If you wish to serve as lead plaintiff, you must move the Court no later than May 18, 2015. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.
Please visit our website at http://www.gme-law.com for more information about the firm.